



**Fluidigm is actively engaged in responding to the COVID-19 crisis on three fronts:**

**1) We are making sure that our employees are safe while we continue our work.**

- Although California has issued Stay at Home orders, biotechnology companies are excluded from this action.
- Essential employees are still working in our offices and we have implemented health and safety practices in accordance with government and public agency guidelines.
- Employees who can perform their duties remotely, are working from home.

**2) We are actively engaged with and supporting our customers and the research community globally to make progress against the pandemic.**

- Our microfluidics and mass cytometry products are critical tools for virus detection and immune profiling work.
- We believe that our tools will be important longer-term as government and medical institutions will need these capabilities to meet these challenges in the future.
- On March 16, we announced that [Mount Sinai and a consortium of medical schools will be seeking Emergency Use Authorization for a COVID-19 early-detection test utilizing Fluidigm Biomark HD and our microfluidics technology.](#)
- A recently published study utilized our mass cytometry technology for patient immune profiling before and after stem cell transplants for 7 severe COVID-19 pneumonia patients.<sup>1</sup>
  - [The study](#) suggests that mesenchymal stem cells could cure or significantly improve the functional outcomes of seven patients without observed adverse effects.
  - This work was led by Chinese researchers in global collaboration with researchers in Asia, the US, and Europe.

**3) We have a healthy balance sheet and are focused on preserving our liquidity runway through this crisis.**

- In 2019, we significantly deleveraged our balance sheet:
  - Through the exchange of \$150 million of our 2014 Notes for equity; and
  - Through execution of a private placement of \$55 million in convertible notes in November 2019 that effectively refinanced the remaining portion of the 2014 Notes and extended the maturity date from February 2021 to December 2024.
- We continue to closely manage our cash outflows commensurate with overall market conditions.
- We have a revolving credit facility in place.

**For more information please visit the [Fluidigm COVID-19 Page](#)**

*[1. Leng, Z. et al. "Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia" Aging and Disease 11:2 \(2020\): 216-228.](#)*

## **Forward-Looking Statements for Fluidigm**

This COVID-19 update contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding: the use of our products and technology in COVID-19 related testing; our ability and/or the ability of the research institutions utilizing our products and technology to obtain FDA and any other requisite approvals to use our products and technology for diagnostic testing purposes; and our ability to effectively manage our capital resources to meet our needs during the COVID-19 crisis. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to: whether and to what extent our products and technologies will be effective in COVID-19 related testing; our ability to obtain regulatory approval to use our products and technologies for diagnostic purposes; our ability to maintain adequate liquidity given the uncertainty concerning the duration of the business interruption being caused by the COVID-19 crisis; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm's Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

**Fluidigm Products are for Research Use Only. Not for use in diagnostic procedures.**